OCUL OCULAR THERAPEUTIX, INC: institutional ownership and insider trading
281 funds reported holding $2.21B of OCULAR THERAPEUTIX, INC in their latest 13F filings; in Q2 2026 funds net sold $16.7M, with 29 new positions and 40 funds selling out; over the last 12 months insiders bought $461K and sold $3.30M on the open market; over its last four quarters it reported revenue of $52.1M and net income of −$301M.
OCUL revenue and earnings
- Quarter ended Jun 30, 2026: revenue $13.5M, net income −$78.8M, EPS -0.35
- Quarter ended Mar 31, 2026: revenue $10.8M, net income −$88.6M, EPS -0.40
- Quarter ended Dec 31, 2025: revenue $13.3M, net income −$64.7M, EPS -0.27
- Quarter ended Sep 30, 2025: revenue $14.5M, net income −$69.4M, EPS -0.38
Famous investors holding OCUL
- Two Sigma (Two Sigma Investments): $12.0M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $3.72M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $8.01M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $1.22M, 0.0% of the portfolio
Largest institutional holders of OCUL
- FMR LLC — $323M
- Deep Track Capital, LP — $193M
- BlackRock, Inc. (BLK) — $190M
- VANGUARD GROUP INC — $141M
- Avoro Capital Advisors LLC — $123M
- SUMMER ROAD LLC — $120M
- VR Adviser, LLC — $102M
- VANGUARD CAPITAL MANAGEMENT LLC — $86.7M
- PRICE T ROWE ASSOCIATES INC /MD/ — $74.9M
- Logos Global Management LP — $52.0M
Recent OCUL insider trades
- Oct 8, 2026: Anderman Todd sold 11,984 shares ($87.4K)
- Oct 2, 2026: Heier Jeffrey S. sold 10,869 shares ($76.6K)
- Oct 2, 2026: Kaiser Peter sold 9,990 shares ($70.4K)
- Aug 31, 2026: Notman Donald sold 1,099 shares ($11.3K)
5%+ owners
- Deep Track Capital, LP: 9.5% (Schedule 13G/A, filed May 15, 2026)
- BlackRock, Inc.: 7.0% (Schedule 13G/A, filed Jul 29, 2026)